MS4A1 and metastatic malignant neoplasm: FCGR2A, KLHDC8B, DEFA3, IGFBP2, MAOB, ZNF346, ARL2, MMP1, KLHL35, CA1, RP11‐525A16.4, CTD‐2509G16.2, and MS4A1 are differentially expressed in advanced, metastatic cancers.